WO2004034987A2 - Treatment for reactive arthritis or bursitis - Google Patents

Treatment for reactive arthritis or bursitis Download PDF

Info

Publication number
WO2004034987A2
WO2004034987A2 PCT/US2003/032653 US0332653W WO2004034987A2 WO 2004034987 A2 WO2004034987 A2 WO 2004034987A2 US 0332653 W US0332653 W US 0332653W WO 2004034987 A2 WO2004034987 A2 WO 2004034987A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage unit
pharmaceutical formulation
metronidazole
dosage
hydrochloride
Prior art date
Application number
PCT/US2003/032653
Other languages
French (fr)
Other versions
WO2004034987A3 (en
Inventor
Ernest L. Bonner
Robert Hines
Original Assignee
Bonner Ernest L
Robert Hines
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonner Ernest L, Robert Hines filed Critical Bonner Ernest L
Priority to EP03776410A priority Critical patent/EP1558266A4/en
Priority to CA002502397A priority patent/CA2502397A1/en
Priority to JP2004545314A priority patent/JP2006503095A/en
Priority to MXPA05003930A priority patent/MXPA05003930A/en
Priority to AU2003284231A priority patent/AU2003284231A1/en
Publication of WO2004034987A2 publication Critical patent/WO2004034987A2/en
Publication of WO2004034987A3 publication Critical patent/WO2004034987A3/en
Priority to AU2009238327A priority patent/AU2009238327A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • TECHNICAL FIELD This invention relates to an improved pharmaceutical formulation for treatment of symptoms associated in humans with reactive arthritis or idiopathic bursitis.
  • Reactive arthritis refers to a spondyloarthritity which usually arises as a complication of an infection elsewhere in the body. Reactive arthritis can be caused by species of Shigella bacteria (most notably Shigella flexneri), Yersinia enterocolitica, Campylobacter jejuni, several species of Salmonella, genitourinary pathogens, Chlamydia trachomatis, Neisseria gonorrhea, Ureaplasma urealyticum, Streptococcus pyogenes, and other yet unidentified infectious agents. Reactive arthritis commonly occurs in young men and women, but can occur at any age.
  • Sufferers experience joint pain, stiffness, redness or swelling. Common symptoms may include fatigue, malaise, fever, and weight loss.
  • the joints of the lower extremities, including the knee, anlde, and joints of the foot, are the most common sites of involvement, but symptoms can also occur in the wrists, fingers, elbows, shoulders, neck, and lower back. Other symptoms may include urethritis and prostatitis in males, and cervicitis or salpingitis in females.
  • Ocular disease is common ranging from transient, asymptomatic conjunctivitis to aggressive anterior uveitis that occasionally results in blindness. Mucocutaneous lesions and nail changes are frequent. On less frequent or rare occasions manifestations of reactive arthritis include cardiac conduction defects, aortic insufficiency, central or peripheral nervous system lesions, and pleuropulmonary infiltrates.
  • NSATD nonsteroidal anti- inflammatory drugs
  • debilitating symptoms refractory to NSAID therapy may be treated with cytotoxic agents such
  • Minocycline hydrochloride a semisynthetic derivative of tetracycline, is indicated for infections caused by at least Shigella microorganisms,
  • Streptococcus pyogenes and Neisserie gonorrhoeae. It is therefore an accepted treatment in incidents of reactive arthritis triggered by these biological entities.
  • Bursitis is inflammation of a bursa, a thin-walled sac lined with synovial tissue.
  • the function of the bursa is to facilitate movement of tendons and muscles over bony prominences. Bursitis may be caused by excessive frictional forces, trauma, systemic disease such as rheumatoid arthritis or gout, or infection.
  • the most common form of bursitis is subacromial. Trochanteric bursitis causes patients to experience pain over the lateral aspect of the hip and
  • Retrocalcaneal bursitis involves the bursa located between the calcaneus and the posterior surface of the Achilles tendon. Pain is experienced at the back of the heel, and swelling appears on either or both of the medial and lateral sides of the tendon. Retrocalcaneal bursitis occurs in association
  • bursitis generally consists of prevention of the aggravating condition, rest of the involved part, an NSAID, and local steroid injection. In the long term, bursitis can result in loss of use of a joint and chronic pain syndrome.
  • Acyclovir is an anti-viral drug.
  • the chemical name of acyclovir is 2-amino-l,9- dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one.
  • Acyclovir is commercially available under the brand name ZOVLRAX® in capsules, tablets, or suspension.
  • Acyclovir has demonstrated anti-viral activity against herpes simplex virus types I and II, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus, both in vitro and in vivo.
  • Valacyclovir hydrochloride (sold under the brand name Valtrex®) is the hydrochloride salt of L-valyl ester of acyclovir.
  • the chemical name of valacyclovir hydrochloride is Z-valine 2-[(2-amino- l,6-dihydro-6-oxo-9H-purin-9-yl) methoxy] ethyl ester, monohydrochloride.
  • Valacyclovir hydrochloride is rapidly and nearly completely converted to acyclovir in the body.
  • Minocycline hydrochloride is a bacteriostatic antibiotic which exerts its antimicrobial effect by inhibition of bacterial protein synthesis. It has been shown to be effective against gram-negative bacteria, some gram-positive bacteria and other microorganisms.
  • Metronidazole is an oral synthetic antiprotozoal and antibacterial agent. Heretofore it has been indicated for treatment of symptomatic trichomoniasis, intestinal amebiasis, and a wide range of intra-abdominal, skin, and gynecological, bone and joint, and lower respiratory
  • acyclovir beings of reactive arthritis or idiopathic bursitis, or both
  • An alternative formulation comprises the substitution of valacyclovir hydrochloride in place of acyclovir.
  • the pharmaceutical dosages of the compounds of the combination may be administered in capsules,
  • the invention provides a pharmaceutical combination that puts the diseases of reactive
  • Treatment with the combination may effect a cure of reactive arthritis and bursitis, but definitive testing has not been performed to confirm that fact.
  • Another object of the invention is to provide a treatment for conditions in human beings associated with either or both reactive arthritis or idiopathic bursitis that puts the disease being treated into full remission.
  • a further object of the invention is to provide a treatment for any constellation of
  • a still further object of the invention is to provide a combination comprising a
  • An alternate method includes administration of IxiH for those individuals who have tested positively for mycobacterial exposure, along with the underlying combination of L-lysine, minocycline hydrochloride, and metronidazole.
  • Another method described in U.S. Patent No. 6,465,473 Bl to Bonner, et al. includes administration of valacyclovir hydrochloride with the
  • a third method of treatment described in U.S. Patent No. 6,197,776 Bl to Bonner, et al. includes administration of acyclovir with the underlying combination of L-lysine, minocycline hydrochloride, and metronidazole.
  • the preferred embodiment of the present treatment includes administration of acyclovir with the underlying combination of L-lysine, minocycline hydrochloride, and metronidazole.
  • the treatment comprises a pharmaceutical combination including acyclovir, minocycline hydrochloride, and metronidazole.
  • the treatment may include valacyclovir hydrochloride,
  • minocycline hydrochloride and metronidazole. Either of these embodiments may be supplemented with administration of pyridoxine hydrochloride, glucosamine, manganese, vitamin C, and desalinated seawater, such as Essence of Life.
  • Administration will generally be accomplished orally via capsules, tablets, or in suspension form, but delivery could be accomplished by injection, or any other method commonly used for administration of internal medicines.
  • acyclovir inhibits herpes simplex viruses, but by a different mechanism.
  • acyclovir inhibits effective replication of actively replicating viral particles by stopping replication of herpes viral DNA. This is accomplished by either competitive
  • the daily dose of acyclovir may vary from 200 mg to 4 grams.
  • the preferred dose of acyclovir is 400 mg twice daily.
  • the preferred dose of minocycline hydrochloride is an initial dosage of 200 mg followed by doses of 100 mg twice per day. Daily doses of minocycline hydrochloride following the initial administration of 200 mg may vary from 50 mg to 200 mg. Based upon their similar properties, it is expected that other members of the tetracycline family such as doxycycline can be effectively substituted, in the combination, for minocycline hydrochrloride.
  • the preferred dose of metronidazole is 250-500 mg twice per day.
  • the total dose per day of metronidazole may vary from 100 mg to 1,000 mg.
  • lysine, minocycline hydrochloride, and metronidazole provides a medically effective treatment for reactive arthritis and bursitis. See U.S. Patent No. 6,087,382. It has also been shown that
  • the preferred embodiment of the present invention comprises the combination of acyclovir or its prodrug, valacyclovir, with minocycline hydrochloride and metronidazole. It is believed that acyclovir results in a substantial benefit due to its inhibition of virus replication.
  • arthritis and what has previously been referred to as idiopathic bursitis, and further is a beneficial treatment for reactive arthritis in particular cases wherein the symptom complex has been misdiagnosed as osteoarthritis or psoriatic arthritis, or in any other similar cases of misdiagnosis.
  • Example 1 A 54 year old male presented with joint pain in his neck, upper back, lower back, both shoulders, both elbows, both wrists, both hands, both hips, both ankles, both knees, and both
  • hydrochloride 100 mg BID, and metronidazole, 250 mg BID, for 8 weeks.
  • the patient experienced resolution of joint tenderness at all mentioned joints, excepting the PIP joint of the third digit of his right hand and his left knee, though such tenderness had decreased in severity in both those joints; and resolution of knee effusions.
  • the patient experienced stiffness in all aforementioned joints lasting for up to 18 hours daily. After treatment stiffness remained in only four joints for about 10 minutes daily.
  • Example 2 A female, 79 years old presented with tenderness in her left shoulder, right elbow, both hands, both knees, her right hip, both ankles, the Achilles insertion of both feet, her lower back, and both wrists. She also experienced effusio in both knees, and pretibial edema
  • tenderness remained in only the right ankle with a decrease in severity at that joint. Tenderness decreased in severity in each joint from "moderate to severe” before treatment, to "slight" post-treatment. The effusions and pretibial edema had resolved. The patient went from a semi-sedentary state to being able to walk around daily for 20 minutes at a time and was able to resume her shopping activities and performing household chores.

Abstract

A pharmaceutical formulation for treating conditions in human beings associated with either or both reactive arthritis or bursitis comprising a combination of acyclovir, minocycline, hydrochloride, and metronidazole. An alternate treatment comprises the combination of valacyclovir hydrochloride , minocycline hydrochloride, and metronidazole.

Description

TREATMENT FOR REACTIVE ARTHRITIS OR BURSITIS
TECHNICAL FIELD This invention relates to an improved pharmaceutical formulation for treatment of symptoms associated in humans with reactive arthritis or idiopathic bursitis.
INDUSTRIAL APPLICABILITY
Reactive arthritis refers to a spondyloarthritity which usually arises as a complication of an infection elsewhere in the body. Reactive arthritis can be caused by species of Shigella bacteria (most notably Shigella flexneri), Yersinia enterocolitica, Campylobacter jejuni, several species of Salmonella, genitourinary pathogens, Chlamydia trachomatis, Neisseria gonorrhea, Ureaplasma urealyticum, Streptococcus pyogenes, and other yet unidentified infectious agents. Reactive arthritis commonly occurs in young men and women, but can occur at any age.
Sufferers experience joint pain, stiffness, redness or swelling. Common symptoms may include fatigue, malaise, fever, and weight loss. The joints of the lower extremities, including the knee, anlde, and joints of the foot, are the most common sites of involvement, but symptoms can also occur in the wrists, fingers, elbows, shoulders, neck, and lower back. Other symptoms may include urethritis and prostatitis in males, and cervicitis or salpingitis in females. Ocular disease is common ranging from transient, asymptomatic conjunctivitis to aggressive anterior uveitis that occasionally results in blindness. Mucocutaneous lesions and nail changes are frequent. On less frequent or rare occasions manifestations of reactive arthritis include cardiac conduction defects, aortic insufficiency, central or peripheral nervous system lesions, and pleuropulmonary infiltrates.
Treatment of patients suffering from reactive arthritis with nonsteroidal anti- inflammatory drugs ("NSATD") provides some benefit, although symptoms of reactive arthritis are rarely completely alleviated and some patients fail to respond at all. The preferred initial treatment of choice for acute reactive arthritis is indomethacin in divided doses of 75 to 150 milligrams per day. The NSATD of last resort is phenylbutazone, in doses of 100 milligrams
twice or three times per day, because of its potentially serious side effects. Patients with
debilitating symptoms refractory to NSAID therapy may be treated with cytotoxic agents such
as azathioprine or methotrexate, or with sulfasalazine. Tendinitis, other lesions, and uveitis may benefit from corticosteroids. Minocycline hydrochloride, a semisynthetic derivative of tetracycline, is indicated for infections caused by at least Shigella microorganisms,
Streptococcus pyogenes, and Neisserie gonorrhoeae. It is therefore an accepted treatment in incidents of reactive arthritis triggered by these biological entities.
Long-term follow-up studies have suggested that some joint symptoms persist in many, if not most, patients with reactive arthritis. Recurrences of the more acute symptoms are common, and as many as twenty-five percent of patients either become unable to work or are forced to change occupations because of persistent joint problems.
Bursitis is inflammation of a bursa, a thin-walled sac lined with synovial tissue. The function of the bursa is to facilitate movement of tendons and muscles over bony prominences. Bursitis may be caused by excessive frictional forces, trauma, systemic disease such as rheumatoid arthritis or gout, or infection. The most common form of bursitis is subacromial. Trochanteric bursitis causes patients to experience pain over the lateral aspect of the hip and
upper thigh, and tenderness over the posterior aspect of the greater trochanter. Retrocalcaneal bursitis involves the bursa located between the calcaneus and the posterior surface of the Achilles tendon. Pain is experienced at the back of the heel, and swelling appears on either or both of the medial and lateral sides of the tendon. Retrocalcaneal bursitis occurs in association
with spondyloarthritities, rheumatoid arthritis, gout, and trauma.
Treatment of bursitis generally consists of prevention of the aggravating condition, rest of the involved part, an NSAID, and local steroid injection. In the long term, bursitis can result in loss of use of a joint and chronic pain syndrome.
The long term effects of reactive arthritis and bursitis range from chronic pain to
crippling disability. It is also thought that many instances of osteoarthritis and psoriatic arthritis are in actuality reactive arthritis. Unfortunately, current procedures for management treat the symptoms of these diseases rather than their underlying pathogens.
DISCLOSURE OF THE INVENTION
The inventors have discovered that significant benefits can be obtained by treating humans affected with conditions associated with reactive arthritis or bursitis using
combinations of acyclovir, minocycline hydrochloride, and metronidazole or, alternatively, valacyclovir hydrochloride, minocycline hydrochloride, and metronidazole.
Acyclovir is an anti-viral drug. The chemical name of acyclovir is 2-amino-l,9- dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one. Acyclovir is commercially available under the brand name ZOVLRAX® in capsules, tablets, or suspension. Acyclovir has demonstrated anti-viral activity against herpes simplex virus types I and II, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus, both in vitro and in vivo.
Valacyclovir hydrochloride (sold under the brand name Valtrex®) is the hydrochloride salt of L-valyl ester of acyclovir. The chemical name of valacyclovir hydrochloride is Z-valine 2-[(2-amino- l,6-dihydro-6-oxo-9H-purin-9-yl) methoxy] ethyl ester, monohydrochloride. Valacyclovir hydrochloride is rapidly and nearly completely converted to acyclovir in the body.
Minocycline hydrochloride is a bacteriostatic antibiotic which exerts its antimicrobial effect by inhibition of bacterial protein synthesis. It has been shown to be effective against gram-negative bacteria, some gram-positive bacteria and other microorganisms.
Metronidazole is an oral synthetic antiprotozoal and antibacterial agent. Heretofore it has been indicated for treatment of symptomatic trichomoniasis, intestinal amebiasis, and a wide range of intra-abdominal, skin, and gynecological, bone and joint, and lower respiratory
tract and central nervous system infections, bacterial septicemia and endocarditis.
The preferred embodiment of a formulation for treatment of the symptoms in human
beings of reactive arthritis or idiopathic bursitis, or both, comprises the combination of acyclovir, minocycline hydrochloride, and metronidazole. An alternative formulation comprises the substitution of valacyclovir hydrochloride in place of acyclovir. The pharmaceutical dosages of the compounds of the combination may be administered in capsules,
tablets, in suspension form, or by injection.
The invention provides a pharmaceutical combination that puts the diseases of reactive
arthritis and bursitis into remission. Treatment with the combination may effect a cure of reactive arthritis and bursitis, but definitive testing has not been performed to confirm that fact.
It is therefore a primary object of the invention to provide a combination for treating conditions in human beings associated with either or both reactive arthritis or idiopathic bursitis.
Another object of the invention is to provide a treatment for conditions in human beings associated with either or both reactive arthritis or idiopathic bursitis that puts the disease being treated into full remission.
A further object of the invention is to provide a treatment for any constellation of
symptoms amenable to treatment using the above combination, including for example, cases of reactive arthritis which have been misdiagnosed as osteoarthritis or psoriatic arthritis.
A still further object of the invention is to provide a combination comprising a
pharmaceutical carrier for treating conditions in human beings associated with either or both reactive arthritis or idiopathic bursitis. BEST MODE FORCARRYING OUT THE INVENTION
U.S. Patent No. 6,087,382 to Bo ner, et al., describes a method of treatment involving administration of a combination of L-lysine, minocycline hydrochloride, and metronidazole.
An alternate method includes administration of IxiH for those individuals who have tested positively for mycobacterial exposure, along with the underlying combination of L-lysine, minocycline hydrochloride, and metronidazole. Another method described in U.S. Patent No. 6,465,473 Bl to Bonner, et al. includes administration of valacyclovir hydrochloride with the
underlying combination of L-lysine, minocycline hydrochloride, and metronidazole. A third method of treatment, described in U.S. Patent No. 6,197,776 Bl to Bonner, et al. includes administration of acyclovir with the underlying combination of L-lysine, minocycline hydrochloride, and metronidazole. The preferred embodiment of the present treatment
comprises a pharmaceutical combination including acyclovir, minocycline hydrochloride, and metronidazole. Alternatively, the treatment may include valacyclovir hydrochloride,
minocycline hydrochloride, and metronidazole. Either of these embodiments may be supplemented with administration of pyridoxine hydrochloride, glucosamine, manganese, vitamin C, and desalinated seawater, such as Essence of Life.
Administration will generally be accomplished orally via capsules, tablets, or in suspension form, but delivery could be accomplished by injection, or any other method commonly used for administration of internal medicines. Like L-lysine, acyclovir inhibits herpes simplex viruses, but by a different mechanism.
While L-lysine tends to stop the virus from replicating by inhibiting the initiation of the
replication process, acyclovir inhibits effective replication of actively replicating viral particles by stopping replication of herpes viral DNA. This is accomplished by either competitive
inhibition or inactivation of viral DNA polymerase or incorporation an termination of the growing viral DNA chain. In double-blind testing, it has been found that the administration of the combination of acyclovir, minocycline hydrochloride, and metronidazole is an effective treatment for reactive arthritis or bursitis. Acyclovir has never been used in the prior art for
treatment of arthritis or bursitis. It does not appear to be effective alone for the treatment of these diseases. The daily dose of acyclovir may vary from 200 mg to 4 grams. The preferred dose of acyclovir is 400 mg twice daily.
The preferred dose of minocycline hydrochloride is an initial dosage of 200 mg followed by doses of 100 mg twice per day. Daily doses of minocycline hydrochloride following the initial administration of 200 mg may vary from 50 mg to 200 mg. Based upon their similar properties, it is expected that other members of the tetracycline family such as doxycycline can be effectively substituted, in the combination, for minocycline hydrochrloride.
The preferred dose of metronidazole is 250-500 mg twice per day. The total dose per day of metronidazole may vary from 100 mg to 1,000 mg.
It is known that the combination of minocycline hydrochloride, InH, and metronidazole inhibits the multiplication of susceptible organisms, including shigella, salmonella, chlamydia, streptococci, and mycobacteria. Applicants have also determined that the combination of L-
lysine, minocycline hydrochloride, and metronidazole provides a medically effective treatment for reactive arthritis and bursitis. See U.S. Patent No. 6,087,382. It has also been shown that
the combination of acyclovir, L-lysine, minocycline hydrochloride, and metronidazole provides an effective treatment for these conditions. See U.S. Patent No. 6,197,776. Individuals with severe symptoms, including joint swelling and joint contractures, who were not thought to be candidates for treatment using the combination of L-lysine, minocycline hydrochloride, and metronidazole only, have also experienced substantial beneficial effects in response to treatment with that combination and valacyclovir hydrochloride.
The preferred embodiment of the present invention comprises the combination of acyclovir or its prodrug, valacyclovir, with minocycline hydrochloride and metronidazole. It is believed that acyclovir results in a substantial benefit due to its inhibition of virus replication.
The total combination of medicines in each of these embodiments presents a broad spectrum approach that it is believed effectively addresses the underlying pathogenesis for reactive
arthritis and what has previously been referred to as idiopathic bursitis, and further is a beneficial treatment for reactive arthritis in particular cases wherein the symptom complex has been misdiagnosed as osteoarthritis or psoriatic arthritis, or in any other similar cases of misdiagnosis.
Examples The following examples serve to illustrate the invention, but are not meant to restrict its effective scope.
Example 1 A 54 year old male presented with joint pain in his neck, upper back, lower back, both shoulders, both elbows, both wrists, both hands, both hips, both ankles, both knees, and both
Achilles tendons at insertion. This patient also had effusion in both knees. He was unable to run or jog, had extreme difficulty squatting, was unable to fully squat, and had difficulty arising from a sitting position. He was treated with acyclovir, 400 mg BID, minocycline
hydrochloride, 100 mg BID, and metronidazole, 250 mg BID, for 8 weeks. The patient experienced resolution of joint tenderness at all mentioned joints, excepting the PIP joint of the third digit of his right hand and his left knee, though such tenderness had decreased in severity in both those joints; and resolution of knee effusions. Before treatment, the patient experienced stiffness in all aforementioned joints lasting for up to 18 hours daily. After treatment stiffness remained in only four joints for about 10 minutes daily.
Example 2 A female, 79 years old presented with tenderness in her left shoulder, right elbow, both hands, both knees, her right hip, both ankles, the Achilles insertion of both feet, her lower back, and both wrists. She also experienced effusio in both knees, and pretibial edema
bilaterally. This individual had stiffness in her joints for about 4 hours a day. After treatment
with acyclovir, 400 mg BID, minocycline hydrochloride, 100 mg BID, and metronidazole, 250 mg BID, for 8 weeks, tenderness remained in only the right ankle with a decrease in severity at that joint. Tenderness decreased in severity in each joint from "moderate to severe" before treatment, to "slight" post-treatment. The effusions and pretibial edema had resolved. The patient went from a semi-sedentary state to being able to walk around daily for 20 minutes at a time and was able to resume her shopping activities and performing household chores.
There have been thus described certain preferred embodiments of a pharmaceutical formulation for treatment of conditions in human beings associated with either or both reactive arthritis or idiopathic bursitis. While preferred embodiments have been described and
disclosed, it will be recognized by those with skill in the art that modifications are within the true scope and spirit of the invention. The appended claims are intended to cover all such modifications.

Claims

We claim: 1. A pharmaceutical formulation for use in treating reactive arthritis or bursitis in a
mammal, including a human, comprising: an effective amount of the combination of a first dosage unit comprising acyclovir or a pharmaceutically acceptable ester thereof, a second dosage unit comprising a member of the tetracycline family, and a third dosage unit comprising metronidazole.
2. A pharmaceutical formulation comprising a combination according to claim 1 wherein: said member of the tetracycline family comprises minocycline hydrochloride.
3. A pharmaceutical formulation comprising a combination according to claim 2 in association with one or more pharmaceutically acceptable carriers therefor.
4. A pharmaceutical formulation according to claim 2 suitable for oral administration.
5. A pharmaceutical formulation according to claim 3 wherein: said first dosage unit of acyclovir is a dosage amount within the range of about 200 mg to 4 gm, said second dosage unit of minocycline hydrochloride is a dosage amount within
the range of about 50-200 mg, and said third dosage unit of metronidazole is a dosage amount within the range of about 100 - 1,000 mg.
6. A pharmaceutical formulation according to claim 5 wherein: said first dosage unit of acyclovir is a dosage amount of about 400 mg, said second dosage unit of minocycline hydrochloride is a dosage amount of about 100 mg, and said third dosage unit of metronidazole is a dosage amount of about 250 mg.
7. A pharmaceutical formulation comprising a combination according to claim 1 wherein:
said pharmaceutically acceptable ester of acyclovir comprises a pharmaceutically acceptable salt of said ester.
8. A pharmaceutical formulation according to claim 7 wherein: said pharmaceutically acceptable salt of said ester is valacyclovir hydrochloride.
9. A pharmaceutical formulation according to claim 2 wherein: said pharmaceutically acceptable ester is valacyclovir hydrochloride.
10. A pharmaceutical formulation for use in treating reactive arthritis or bursitis in a mammal, including a human, comprising:
an effective amount of the combination of a first dosage unit comprising valacyclovir hydrochloride, a second dosage unit comprising a member of the tetracycline family, and a third dosage unit comprising metronidazole.
11. A pharmaceutical formulation comprising a combination according to claim 10 wherein:
said member of the tetracycline family comprises minocycline hydrochloride.
12. A pharmaceutical formulation comprising a combination according to claim 11 in association with one or more pharmaceutically acceptable carriers therefor.
13. A formulation according to claim 11 suitable for oral administration.
14. A formulation according to claim 12 wherein: said first dosage unit of valacyclovir hydrochloride is a dosage amount within the range of about 200 mg to 4 gm, said second dosage unit of minocycline hydrochloride is a dosage amount within the range of about 50-200 mg, and said third dosage unit of metronidazole is a dosage amount within the range of about 100 - 1,000 mg.
15. A pharmaceutical formulation according to claim 14 wherein:
said first dosage unit of valacyclovir hydrochloride is a dosage amount of about 400 mg, said second dosage unit of minocycline hydrochloride is a dosage amount of about 100 mg, and said third dosage unit of metronidazole is a dosage amount within the range of about 250 mg.
PCT/US2003/032653 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis WO2004034987A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03776410A EP1558266A4 (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis
CA002502397A CA2502397A1 (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis
JP2004545314A JP2006503095A (en) 2002-10-15 2003-10-14 Treatment of reactive arthritis or bursitis
MXPA05003930A MXPA05003930A (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis.
AU2003284231A AU2003284231A1 (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis
AU2009238327A AU2009238327A1 (en) 2002-10-15 2009-11-18 Treatment for reactive arthritis or bursitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/271,117 2002-10-15
US10/271,117 US6765000B2 (en) 1999-03-17 2002-10-15 Treatment for reactive arthritis or bursitis

Publications (2)

Publication Number Publication Date
WO2004034987A2 true WO2004034987A2 (en) 2004-04-29
WO2004034987A3 WO2004034987A3 (en) 2004-07-15

Family

ID=32106409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032653 WO2004034987A2 (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis

Country Status (10)

Country Link
US (3) US6765000B2 (en)
EP (1) EP1558266A4 (en)
JP (1) JP2006503095A (en)
KR (1) KR20050083762A (en)
CN (1) CN100584335C (en)
AU (2) AU2003284231A1 (en)
CA (1) CA2502397A1 (en)
CH (1) CH696629A5 (en)
MX (1) MXPA05003930A (en)
WO (1) WO2004034987A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US20050137181A1 (en) * 1999-03-17 2005-06-23 Bonner Ernest L. Method for treatment of reactive arthritis or bursitis
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US7691831B2 (en) * 1999-03-17 2010-04-06 Ernest L. Bonner, Jr. Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
CN1293883C (en) * 2004-05-21 2007-01-10 邹宏 Wipe-off and recovery treatment lotion and preparation method thereof
US7312343B2 (en) * 2004-06-02 2007-12-25 Hoffmann-La Roche Inc. Synthesis of α-amino-β-alkoxy-carboxylic acid esters
WO2006064516A1 (en) * 2004-12-17 2006-06-22 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
US20100144671A1 (en) * 2005-03-04 2010-06-10 Women And Infants Hospital Of Ri, Inc. Compositions and Methods for Cancer Treatment
CN101678108A (en) * 2007-03-23 2010-03-24 分子研究中心公司 Comprise anti-inflammatory composition of Tetracyclines and uses thereof
CA2609104C (en) * 2007-04-10 2017-09-05 Exist Marketing Pty Ltd Method and device for treating bursitis
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
EP2884974B1 (en) * 2014-08-18 2017-02-22 Fabrizio De Silvestri Use in one pill/tablet/capsule minocycline, acycloguanosine, atorvastatin and vitamin d3 in the treatment of rheumatoid arthritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6093414A (en) * 1997-08-11 2000-07-25 Christopher C. Capelli Silver-based antimicrobial compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946801A (en) 1957-06-05 1960-07-26 Standard Oil Co Production of pyridine carboxylic acids
US3148212A (en) 1961-12-22 1964-09-08 American Cyanamid Co Reductive alkylation process
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US4177796A (en) 1977-08-22 1979-12-11 Franco Vila Jose J Magnetic thermal vibrational device for the treatment of arthritis and the like
US4521411A (en) 1983-11-04 1985-06-04 Theodora Koloff Analgesic composition
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
WO1994023593A1 (en) * 1993-04-16 1994-10-27 Mccormick & Company, Inc. Encapsulation compositions
GB9425487D0 (en) 1994-12-16 1995-02-15 Res Inst Osteoarthritis treatment
JPH09136842A (en) * 1995-11-14 1997-05-27 Shigemasa Sawada Anti-rheumatoid arthritis agent
US5952367A (en) 1997-04-25 1999-09-14 Pak; Kyoungsik Method of treating pain cause by bursitis tendinitis arthritis
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6087382A (en) * 1999-03-17 2000-07-11 Bonner, Jr.; Ernest L. Method for treatment of reactive arthritis or bursitis
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
US6765000B2 (en) 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US20050137181A1 (en) 1999-03-17 2005-06-23 Bonner Ernest L. Method for treatment of reactive arthritis or bursitis
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US20040015367A1 (en) * 2000-10-30 2004-01-22 Nicastro Cherisse M. Business asset management system using virtual areas
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
US20040024624A1 (en) * 2002-07-31 2004-02-05 Ciscon Lawrence A. Method and system for leveraging functional knowledge using a requirement and space planning tool in an engineering project

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6093414A (en) * 1997-08-11 2000-07-25 Christopher C. Capelli Silver-based antimicrobial compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1558266A2 *

Also Published As

Publication number Publication date
CN100584335C (en) 2010-01-27
US7053073B2 (en) 2006-05-30
US6765000B2 (en) 2004-07-20
US20050059640A1 (en) 2005-03-17
AU2003284231A1 (en) 2004-05-04
WO2004034987A3 (en) 2004-07-15
KR20050083762A (en) 2005-08-26
US20030055022A1 (en) 2003-03-20
MXPA05003930A (en) 2005-06-17
EP1558266A4 (en) 2007-12-26
CH696629A5 (en) 2007-08-31
EP1558266A2 (en) 2005-08-03
CA2502397A1 (en) 2004-04-29
US20050176690A1 (en) 2005-08-11
AU2009238327A1 (en) 2009-12-10
CN1729006A (en) 2006-02-01
JP2006503095A (en) 2006-01-26

Similar Documents

Publication Publication Date Title
AU2009238327A1 (en) Treatment for reactive arthritis or bursitis
US6465473B1 (en) Method for treatment of reactive arthritis or bursitis
US6197776B1 (en) Method for treatment of reactive arthritis or bursitis
CN111904962A (en) Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor
AU2001280519A1 (en) Method for treatment of reactive arthritis or bursitis
WO1998042188A1 (en) Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
Wang et al. Treatment with total alkaloids from Radix Linderae reduces inflammation and joint destruction in type II collagen-induced model for rheumatoid arthritis
US20050137181A1 (en) Method for treatment of reactive arthritis or bursitis
US7691831B2 (en) Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
CN111939179B (en) Application of cobra venom or cobra venom extract in preparation of medicine for reducing uric acid and/or resisting gouty arthritis
JP2006515361A (en) Method for treating or preventing symptoms of herpes virus infection
JP4693241B2 (en) Riluzole and α-tocopherol combination
CN113825512A (en) Treatment of cutaneous lupus erythematosus
US20240033309A1 (en) Combination therapy for inflammatory disorders of the joints
KR101213601B1 (en) Compositions for the herpes infection containing decursin and/or decursinol angelate, or angelica extract containing decursin and/or decursinol angelate
CN114980876A (en) Treatment of primary biliary cholangitis with elafeinuo
TABLETS SILENCE FEAR. SILENCE INFECIlON.
UA7302U (en) Method for complex treatment of lambliasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 167991

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003930

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2502397

Country of ref document: CA

Ref document number: 1020057006451

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004545314

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003284231

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003776410

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A36532

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003776410

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057006451

Country of ref document: KR